摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trans-4-[4-(2,4-dioxo-1,4-dihydroquinazolin-3-ylmethyl)cyclohexanecarbonyl]piperazine-1-carboxylic acid tert-butyl ester

中文名称
——
中文别名
——
英文名称
trans-4-[4-(2,4-dioxo-1,4-dihydroquinazolin-3-ylmethyl)cyclohexanecarbonyl]piperazine-1-carboxylic acid tert-butyl ester
英文别名
4-[trans-4-(2,4-dioxo-1,4-dihydro-2H-quinazolin-3-ylmethyl)cyclohexanecarbonyl]-piperazine-1-carboxylic acid tert-butyl ester;tert-butyl 4-[4-[(2,4-dioxo-1H-quinazolin-3-yl)methyl]cyclohexanecarbonyl]piperazine-1-carboxylate
trans-4-[4-(2,4-dioxo-1,4-dihydroquinazolin-3-ylmethyl)cyclohexanecarbonyl]piperazine-1-carboxylic acid tert-butyl ester化学式
CAS
——
化学式
C25H34N4O5
mdl
——
分子量
470.569
InChiKey
DKZNEKIHGOUTTL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    34
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    99.3
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    trans-4-[4-(2,4-dioxo-1,4-dihydroquinazolin-3-ylmethyl)cyclohexanecarbonyl]piperazine-1-carboxylic acid tert-butyl ester硫酸N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 36.0h, 生成 trans-3-[4-(4-cyclopropanecarbonylpiperazine-1-carbonyl)cyclohexylmethyl]-1H-quinazoline-2,4-dione
    参考文献:
    名称:
    Structure–activity relationship and properties optimization of a series of Quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway
    摘要:
    Wnt signaling pathway plays a critical role in numerous cellular processes, including tumor initiation, proliferation, invasion/infiltration, metastasis formation and resistance to chemotherapy. In a drug discovery project aimed at the identification of inhibitors of the canonical Wnt pathway, we selected a series of quinazoline 2,4-diones as starting point for the therapeutic treatment of glioblastoma multiforme. Despite of poor physico-chemical properties of hit compound I, our medicinal chemistry effort allowed the discovery and characterization of lead compound 33 (SEN461), with improved ADME profile, good bioavailability and active in vitro and in vivo in glioblastoma, gastric and sarcoma tumors. (C) 2015 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2015.03.055
  • 作为产物:
    描述:
    trans-4-aminomethyl-cyclohexanecarboxylic acid methyl ester 在 potassium carbonateN,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 lithium hydroxide 作用下, 以 四氢呋喃N,N-二甲基甲酰胺乙腈 为溶剂, 反应 54.0h, 生成 trans-4-[4-(2,4-dioxo-1,4-dihydroquinazolin-3-ylmethyl)cyclohexanecarbonyl]piperazine-1-carboxylic acid tert-butyl ester
    参考文献:
    名称:
    Structure–activity relationship and properties optimization of a series of Quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway
    摘要:
    Wnt signaling pathway plays a critical role in numerous cellular processes, including tumor initiation, proliferation, invasion/infiltration, metastasis formation and resistance to chemotherapy. In a drug discovery project aimed at the identification of inhibitors of the canonical Wnt pathway, we selected a series of quinazoline 2,4-diones as starting point for the therapeutic treatment of glioblastoma multiforme. Despite of poor physico-chemical properties of hit compound I, our medicinal chemistry effort allowed the discovery and characterization of lead compound 33 (SEN461), with improved ADME profile, good bioavailability and active in vitro and in vivo in glioblastoma, gastric and sarcoma tumors. (C) 2015 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2015.03.055
点击查看最新优质反应信息

文献信息

  • [EN] WNT PATHWAY ANTAGONISTS<br/>[FR] ANTAGONISTES DE LA VOIE WNT
    申请人:SIENA BIOTECH SPA
    公开号:WO2011042145A1
    公开(公告)日:2011-04-14
    The present invention relates to known and novel compounds of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) have inhibitory effect on the Wnt pathway and are therefore useful in the preparation of a medicament, in particular for the treatment of cancer.
    本发明涉及如下所述的已知和新颖的化合物(I)的公式及其药物组成。公式(I)的化合物对Wnt途径具有抑制作用,因此在制备药物方面特别适用于治疗癌症。
  • WNT PATHWAY ANTAGONISTS
    申请人:Varrone Maurizio
    公开号:US20120196851A1
    公开(公告)日:2012-08-02
    The present invention relates to known and novel compounds of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) have inhibitory effect on the Wnt pathway and are therefore useful in the preparation of a medicament, in particular for the treatment of cancer.
    本发明涉及公知和新颖的化合物(I)及其药物组合物。化合物(I)对Wnt通路具有抑制作用,因此在制备药物中特别适用于癌症的治疗。
  • US8865704B2
    申请人:——
    公开号:US8865704B2
    公开(公告)日:2014-10-21
  • Structure–activity relationship and properties optimization of a series of Quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway
    作者:Arianna Nencini、Carmela Pratelli、Joanna M. Quinn、Massimiliano Salerno、Patrizia Tunici、Alessandra De Robertis、Silvia Valensin、Federica Mennillo、Marco Rossi、Annette Bakker、Tiziana Benicchi、Federico Cappelli、Elisa Turlizzi、Martina Nibbio、Nicola P. Caradonna、Ugo Zanelli、Matteo Andreini、Matteo Magnani、Maurizio Varrone
    DOI:10.1016/j.ejmech.2015.03.055
    日期:2015.5
    Wnt signaling pathway plays a critical role in numerous cellular processes, including tumor initiation, proliferation, invasion/infiltration, metastasis formation and resistance to chemotherapy. In a drug discovery project aimed at the identification of inhibitors of the canonical Wnt pathway, we selected a series of quinazoline 2,4-diones as starting point for the therapeutic treatment of glioblastoma multiforme. Despite of poor physico-chemical properties of hit compound I, our medicinal chemistry effort allowed the discovery and characterization of lead compound 33 (SEN461), with improved ADME profile, good bioavailability and active in vitro and in vivo in glioblastoma, gastric and sarcoma tumors. (C) 2015 Elsevier Masson SAS. All rights reserved.
查看更多